Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
ADVISORY, Jan. 19, 2018 --
WHAT: Dr. Heinrich Roder, Biodesix’ CTO, will speak on “Applied Machine Learning for Immuno-Oncology Diagnostics” in the “AI and Data Science Showcase” track at the Precision Medicine World Conference (PMWC) in Mountain View, CA.
WHO: Heinrich Roder is a company founder and author or co-author of more than 100 publications and talks spanning the fields of theoretical physics, computational sciences, and molecular diagnostics. A Rhodes Scholar, he earned his DPhil in Theoretical Physics from the University of Oxford and has held positions at the Universities of Hanover and Bayreuth and at Los Alamos National Laboratory. He is a founder of Biodesix. Serving as CTO, he leads the work of the Research and Development team on sensitive, high-throughput MALDI-ToF mass spectrometry profiling of blood-based samples. His team develops molecular diagnostic tests using a proprietary analytics platform based on machine learning.
WHEN/WHERE: Monday, January 22nd, 10:30AM PST, at the Computer History Museum, 1401 N. Shoreline Blvd, Mountain View, CA.
About Biodesix
Biodesix® is a molecular diagnostics company advancing the development of innovative blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of precision medicine, Biodesix is developing new blood tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.
For more information about Biodesix, please visit www.Biodesix.com.
Contact: Rachel Biederman
720-214-5774
[email protected]
